Avalo Therapeutics Inc, a clinical-stage biotech firm based in Rockville, Maryland with 20 employees, focuses on developing therapies targeting the LIGHT-signaling network for immune dysregulation. Their key products include AVTX-002 for various disorders and AVTX-008, a BTLA agonist fusion protein, with the company going public in 2015.
Avalo Therapeutics (AVTX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Avalo Therapeutics's actual EPS was -$14.07, missing the estimate of -$6.83 per share, resulting in a -105.88% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
